471930-01-5

Usage

Uses

Used in Flavoring and Fragrance Industry:
3-(PIPERIDINOMETHYL)BENZALDEHYDE is used as a flavoring agent for its sweet, floral odor, enhancing the taste and aroma of various food products.
Used in Perfumery and Cosmetics Industry:
3-(PIPERIDINOMETHYL)BENZALDEHYDE is used as a fragrance ingredient in perfumes and cosmetics, contributing to their pleasant and appealing scents.
Used in Pharmaceutical Industry:
3-(PIPERIDINOMETHYL)BENZALDEHYDE is used as a key intermediate in the synthesis of pharmaceuticals, playing a crucial role in the development of new drugs.
Used in Organic Synthesis:
3-(PIPERIDINOMETHYL)BENZALDEHYDE is used as a building block in the synthesis of other organic compounds, showcasing its versatility in chemical reactions.

InChI:InChI=1/C13H17NO/c15-11-13-6-4-5-12(9-13)10-14-7-2-1-3-8-14/h4-6,9,11H,1-3,7-8,10H2

Upstream product

• 73278-90-7 methyl 3-[(piperidin-1-yl)methyl]-benzoate 
• 110-89-4 piperidine 
• 52178-50-4 Methyl 3-formylbenzoate 
• 73278-91-8 3-(1-piperidinylmethyl)benzenemethanol 

Downstream Products

• 1119280-79-3 (E)-5,6-dimethoxy-2-{3-[(piperidin-1-yl)methyl]-benzylidene}-2,3-dihydroinden-1-one 

Relevant academic research and scientific papers

Synthesis and in Vitro Anticancer Activity of the First Class of Dual Inhibitors of REV-ERBβ and Autophagy

Autophagy inhibition is emerging as a promising anticancer strategy. We recently reported that the circadian nuclear receptor REV-ERBβ plays an unexpected role in sustaining cancer cell survival when the autophagy flux is compromised. We also identified 4-[[[1-(2-fluorophenyl)cyclopentyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol, 1 (ARN5187), as a novel dual inhibitor of REV-ERBβ and autophagy. 1 had improved cytotoxicity against BT-474 breast cancer cells compared to chloroquine, a clinically relevant autophagy inhibitor. Here, we present the results of structure-activity studies, based around 1, that disclose the first class of dual inhibitors of REV-ERBβ and autophagy. This study led to identification of 18 and 28, which were more effective REV-ERBβ antagonists than 1 and were more cytotoxic to BT-474. The combination of optimal chemical and structural moieties of these analogs generated 30, which elicited 15-fold greater REV-ERBβ inhibitory and cytotoxic activities compared to 1. Furthermore, 30 induced death in a panel of tumor cell lines at doses 5-50 times lower than an equitoxic amount of chloroquine but did not affect the viability of normal mammary epithelial cells.

DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof : It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and pro-apoptotic agents for cancer therapy.

Design, synthesis and AChE inhibitory activity of indanone and aurone derivatives

A new series of indanone and aurone derivatives have been synthesized and tested for in vitro AChE inhibitory activity by modified Ellman method. Most of them exhibit AChE inhibitory activities superior to rivastigmine. Further, the most potent compound 1g was selected to evaluate the effect on the acquisition and memory impairment by mice step-down passive avoidance test.

Imidazolidine compounds

Disclosed are novel compounds and a method of treating inflammatory diseases. The method comprises administering to an individual in need an effective amount of an imidazolidine compound represented by Structural Formula (I): and physiologically or pharma